Publicaciones en colaboración con investigadores/as de PharmaMar (6)

2023

  1. Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma

    Cancer Medicine, Vol. 12, Núm. 4, pp. 3999-4009

2011

  1. Blockade of the NFκB pathway drives differentiating glioblastoma-initiating cells into senescence both in vitro and in vivo

    Oncogene, Vol. 30, Núm. 32, pp. 3537-3548

  2. Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response

    Haematologica, Vol. 96, Núm. 5, pp. 687-695

2009

  1. DNA DSBs Induction by Zalypsis, a Novel Marine Compound, Results in Potent Antimyeloma Activity

    CLINICAL LYMPHOMA & MYELOMA

  2. Zalypsis: A novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks

    Blood, Vol. 113, Núm. 16, pp. 3781-3791

2008

  1. Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo

    Cancer Research, Vol. 68, Núm. 13, pp. 5216-5225